Loading
Fennec Pharmaceuticals Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 19 May 2025.
Fennec Pharmaceuticals Inc.: what insiders have been doing
Fennec Pharmaceuticals Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). The last twelve months, up to 18 October 2026, brought 133 filings signed by 22 insiders.
On the market, 6 insiders bought (31 purchases totalling €56k) while 9 insiders sold (19 sales totalling €10.2M). The totals exclude 26 filings filed without an amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Those buying include 6 senior executives. One trade stands out by size: a sale of €6.4M from Southpoint Capital Advisors LP, disclosed on 29 December 2025.
With 133 filings in twelve months, the company is more active than the median of 19 filings across the 5,813 companies we follow on the same exchange. Looking back to 2021, when coverage begins, insiders filed 34 purchases and 50 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 44.6 m USD and net income of -9.7 m USD.
The clock since the last published purchase (14 October 2026) now reads 3 days. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4.
Elsewhere in the same sector, our signals recently picked up insider purchases at MAIA Biotechnology, Inc. and Cooper Companies, Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
231
Thresholds
n/a
Buy Volume
€62,410
34 ops. · all time
Sell Volume
€12M
50 ops. · all time
Who traded when
BuySaleRaykov Rosty17 sales
Robert Christopher Andrade7 buys2 sales
Pierre Sayad6 buys1 sale
Christiana Cioffi6 buys
Jeffrey Hackman6 buys
Terry Evans6 buys
+7 other insiders
Since the insiders bought
- +19.3%Entry US$8.17 · Close at T+365 US$9.75
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Fennec Pharmaceuticals Inc. Strong Buy (bullish), based on 6 analysts. Average price target: US$17.67.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 19,036 of 24,148 companies
31.8
score / 100
Value25
Quality39
FCF yld-3.6%
Earn yld-2.8%
EV/EBITDA·
ROE-19%
Gross mgn92%
Net mgn-22%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$10.18
Analyst consensus
6 analystsStrong buy
US$16.00Target US$17.67(+74%)US$20.00
Income statement
RevenueUS$44.6M
Gross profitUS$40.9M92% margin
EBITDA-US$7.5M-17% margin
Net income-US$9.7M-5.5% margin
Valuation
PER (forward)10.7x
P/Book8.4x
Beta1.23
Balance sheet & cash
Market capUS$357M
Free Cash Flow-US$12.5M
Profitability & ownership
ROE-18.6%
ROA-1.2%
% insiders14.1%
% institutions54.2%
Last declaration on 14 October 2026
Declarations231 total
3,846 shares@ CA$5.53Common SharesTSXSEDI:4791130
Canonical exit: 10 Jan 2027 (T+90)
2,224 shares@ CA$5.53Common SharesTSXSEDI:4791128
Canonical exit: 10 Jan 2027 (T+90)
2,326 shares@ CA$5.53Common SharesTSXSEDI:4791124
Canonical exit: 10 Jan 2027 (T+90)
3,946 shares@ CA$5.53Common SharesTSXSEDI:4791121
Canonical exit: 10 Jan 2027 (T+90)
3,846 shares@ CA$5.53Common SharesTSXSEDI:4791107
Canonical exit: 10 Jan 2027 (T+90)
2,326 shares@ US$5.530.0034% mcap100.0% of flowCommon SharesSEC:0002043317-26-000016:0
3,846 shares@ US$5.530.0056% mcap13.1% of flowCommon SharesSEC:0002043395-26-000016:0
2,224 shares@ US$5.530.0033% mcap63.7% of flowCommon SharesSEC:0001926254-26-000018:0
3,946 shares@ US$5.530.0058% mcap53.1% of flowCommon sharesSEC:0002043411-26-000018:0
3,846 shares@ US$5.530.0056% mcap1.1% of flowCommon sharesSEC:0001468308-26-000034:0
1,159 sharesCommon SharesTSXSEDI:4783544
Canonical exit: 30 Dec 2026 (T+90)
1,703 sharesCommon SharesTSXSEDI:4783539
Canonical exit: 30 Dec 2026 (T+90)
168 sharesCommon SharesTSXSEDI:4783522
Canonical exit: 30 Dec 2026 (T+90)
156 sharesCommon SharesTSXSEDI:4783415
Canonical exit: 30 Dec 2026 (T+90)
168 sharesCommon SharesTSXSEDI:4783393
Canonical exit: 30 Dec 2026 (T+90)
168 shares0Common SharesSEC:0002043395-26-000014:0
168 shares0Common SharesSEC:0002043317-26-000014:0
1,159 shares0Common SharesSEC:0001926254-26-000016:0
156 shares0Common sharesSEC:0002043411-26-000016:0
1,703 shares0Common sharesSEC:0001468308-26-000032:0
15,545 shares@ CA$10.290.031% mcap43.7% of flowCommon SharesTSXSEDI:4779423
Common SharesTSXSEDI:4779411
15,545 shares@ CA$2.110.0063% mcap9.0% of flowOptionsTSXSEDI:4779401
15,545 shares@ US$10.290.043% mcap83.0% of flowCommon SharesSEC:0001589776-26-000004:1
15,545 shares@ US$2.110.0088% mcap17.0% of flowCommon SharesSEC:0001589776-26-000004:0
25 of 231 declarations
About Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company listed on the NASDAQ (ticker: FENC) in the United States. The company is headquartered in Research Triangle Park, North Carolina, and it focuses on a highly specific oncology-supportive-care niche: reducing cisplatin-induced ototoxicity in pediatric patients with localized, non-metastatic solid tumors. Its core asset is PEDMARK® (sodium thiosulfate injection), which received FDA approval in September 2022 and began U.S. commercial availability in October 2022. Outside the United States, the same product is marketed as PEDMARQSI®, with approvals in Europe and the United Kingdom, giving Fennec a broader international runway than its domestic profile alone might suggest.([investors.fennecpharma.com](https://investors.fennecpharma.com/?utm_source=openai))
From a corporate history standpoint, Fennec was originally incorporated in British Columbia under the name Adherex Technologies Inc. and later changed its name to Fennec Pharmaceuticals Inc. in 2014. That evolution matters for investors because it reflects a transition from earlier-stage development activities toward a commercial-stage model anchored by one lead branded therapy. Today, the company’s business is concentrated almost entirely on PEDMARK in the U.S. market, supported by the Fennec HEARS™ patient-support platform, which is designed to help families and providers navigate access, reimbursement, and treatment logistics.([sec.gov](https://www.sec.gov/Archives/edgar/data/1211583/000155837025003710/fencf-20241231x10k.htm?utm_source=openai))
Read moreShow less
In competitive terms, Fennec is a focused, specialty player rather than a broad-based oncology company. It is not built around a large diversified pipeline; instead, the investment case depends on the clinical and commercial adoption of a single differentiated product in a well-defined hospital setting. That creates both concentration risk and strategic clarity. The company’s moat is tied to regulatory approvals, the clinical relevance of preventing hearing loss in children receiving cisplatin, and the ability to expand use within oncology care pathways. Internationally, Fennec has extended its reach through licensing rather than direct commercial buildout: in March 2024 it signed an exclusive agreement with Norgine to commercialize PEDMARQSI in Europe, Australia, and New Zealand, which broadens geographic exposure while limiting capital intensity.([sec.gov](https://www.sec.gov/Archives/edgar/data/1211583/000155837025003710/fencf-20241231x10k.htm?utm_source=openai))
Recent developments have been supportive. In March 2026, Fennec reported record full-year 2025 net product sales and described continued quarter-over-quarter growth during 2025. In 2025, it also disclosed positive topline results from an investigator-initiated study in Japan evaluating PEDMARK for cisplatin-induced hearing loss, and it announced additional research collaborations with leading U.S. cancer institutions such as City of Hope and Tampa General Hospital Cancer Institute. For investors, these updates suggest a company moving beyond first commercialization in the United States toward broader evidence generation and potential label/market expansion, while still retaining the risk profile of a small-cap single-product pharmaceutical business.([investors.fennecpharma.com](https://investors.fennecpharma.com/news-releases/news-release-details/fennec-pharmaceuticals-reports-fourth-quarter-and-full-year-2025?utm_source=openai))
